Loxo oncology, inc. (LOXO)
CashFlow / Quarterly
Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Operating activities:
Net loss

-27,064

-11,726

-3,558

-20,628

-73,319

-30,401

-24,528

-27,194

-17,691

-15,916

-11,597

-12,867

-8,771

-8,056

-6,182

-7,122

-6,743

-3,905

-2,902

Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Amortization of premium and discounts on investments

-757

-514

-245

-62

20

46

76

120

162

139

107

106

132

94

59

-

-

-

-

Depreciation of property and equipment

206

106

80

45

32

27

21

33

16

14

14

6

7

3

1

-

-

-

-

Stock-based compensation

11,153

12,346

9,651

4,745

5,267

5,436

3,974

2,566

2,765

1,287

1,342

2,305

1,165

1,635

1,049

477

2,035

473

64

Changes in operating assets and liabilities:
Receivable from collaboration partner

0

-4,529

-145,471

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid expenses and other assets

596

-143

588

981

1,177

-565

1,483

-1,406

1,467

286

-571

272

1,801

169

-271

-

-

-

484

Accounts payable

-2,771

-1,007

1,800

2,167

-346

922

192

40

344

-81

489

-462

316

130

46

32

-369

333

22

Accrued expenses and other current liabilities

9,353

11,840

9

6,896

6,633

-147

-4,928

8,450

514

2,972

-437

476

705

416

-524

-

-

-

-

Deferred revenue

-52,938

-51,228

-42,853

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by (used in) operating activities

-61,431

-34,918

109,767

220,881

-62,890

-23,552

-26,676

-14,579

-15,357

-11,871

-9,511

-10,708

-8,247

-5,947

-5,280

-5,625

-5,627

-3,307

-3,136

Accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

164

Investing activities:
Purchases of available-for-sale securities

137,956

84,254

214,383

214,814

190,986

48,436

120,272

41,698

18,920

59,173

43,499

68,157

28,897

26,401

10,275

-

-

-

-

Proceeds from maturing available-for-sale securities

185,985

158,025

66,888

55,081

73,497

36,875

35,683

34,677

32,941

37,552

31,868

41,326

34,920

31,500

8,900

-

-

-

-

Purchase of property and equipment

1,126

1,861

746

391

234

63

101

12

-6

2

229

20

2

51

20

-

-

-

-

Net cash used in investing activities

46,903

71,910

-148,241

-160,124

-117,723

-11,624

-84,690

-7,033

14,027

-21,623

-11,860

-26,851

6,021

5,048

-1,395

-

-

-

-

Financing activities:
Proceeds from issuance of redeemable convertible preferred stock, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-45

28,223

15,000

Proceeds from issuance of common stock, net

-

-

-

0

30

245,891

129,386

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from the exercise of stock options

2,988

6,879

229

533

735

1,372

100

59

353

120

741

-

-

-

-

0

8

84

75

Net cash provided by financing activities

2,988

6,879

229

533

765

247,263

129,486

59

353

38,853

741

-

-

-

-

0

72,951

27,685

15,075

Net (decrease) increase in cash, cash equivalents, and restricted cash

-11,540

43,871

-38,245

61,290

-179,848

212,087

18,120

-21,553

-977

5,359

-20,630

33,768

-2,226

-620

-6,675

-74,691

67,317

24,371

11,939

Unrealized gain on available for sale securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

21

-

-

-

-

Accretion of redeemable convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

11